Risk factors
Pliant Therapeutics (PLRX) risk factors
Item 1A of every Pliant Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors84 risks15 new9 dropped25 reworded
Discontinuation of the BEACON-IPF Phase 2b trial for bexotegrast drove major restructuring, cost reduction, and strategic alternatives.
Filed Mar 11, 2026 - FY2024 10-K risk factors78 risks
Clinical stage biopharmaceutical company focused on discovering and developing treatments for fibrotic diseases, primarily dependent on lead candidate bexotegrast.
Filed Mar 03, 2025